CIK 0001541157 · Non-accelerated filer<br>Smaller reporting company
Akari Therapeutics Plc
Sign in to watch- Ticker
- AKTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- EIN
- 981034922
- Phone
- (929) 274-7510
- Business address
- 401 EAST JACKSON STREET, SUITE 3300, TAMPA, FL, 33602
- Former names
- Celsus Therapeutics Plc., Morria Biopharmaceuticals PLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-18 | Prudo-Chlebosz Raymond Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2026-08-18 | Prudo-Chlebosz Raymond Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2026-08-18 | Huh Hoyoung Director | Grant or award | +17,249 | $7.90 | $136K | 134,645 |
| 2026-08-18 | Huh Hoyoung Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2026-08-18 | Huh Hoyoung Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2026-08-18 | Patel Sandip I Director | Grant or award | +12,100 | $7.90 | $96K | 24,512 |
| 2026-08-18 | Patel Sandip I Director | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2026-08-18 | Patel Sandip I Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2026-08-18 | Bazemore Robert B Director | Grant or award | +13,100 | $7.90 | $103K | 14,216 |
| 2026-08-18 | Bazemore Robert B Director | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2026-08-18 | Bazemore Robert B Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2026-08-18 | Gaslightwala Abizer CEO | Grant or award · Stock Option (Right to Buy) | +174,000 | 174,000 | ||
| 2026-08-18 | Patel Samir Rashmikant Director | Grant or award | +6,300 | $7.90 | $50K | 9,866 |
| 2026-08-18 | Patel Samir Rashmikant Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2026-08-18 | Patel Samir Rashmikant Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2026-08-17 | Farag Kameel D. Interim CFO | Grant or award | +1,728 | $7.52 | $13K | 23,309 |
| 2026-07-16 | Farag Kameel D. Interim CFO | Grant or award | +1,130 | $11.50 | $13K | 21,581 |
| 2026-07-07 | Patel Samir Rashmikant Director | Option exercise | +1,209 | $8.00 | $10K | 76,976 |
| 2026-07-07 | Patel Samir Rashmikant Director | Option exercise | +15,466 | $0.00 | $6 | 92,442 |
| 2026-07-07 | Patel Samir Rashmikant Director | Option exercise | +5,799 | $0.00 | $2 | 98,241 |
Page 2 of 11 · 216 trades